Mevalonate availability and cardiovascular functions

Jean-Baptiste Roullet, Hong Xue, Anuradha Pappu, Chantal Roullet, Scott Holcomb, David A. Mccarron

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Data delineating the relationship between disorders of cholesterol metabolism and elevated blood pressure (BP) do not exist. We postulated that mevalonate, the metabolic precursor of endogenous cholesterol and the direct product of 3-hydroxy-3-methylglutaryl-CoA reductase, was a contributing factor for the maintenance of vascular tone and systemic BP. We conducted in vivo, ex vivo, and in vitro experiments in normotensive and hypertensive rats, where exogenous mevalonate and lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, were used, respectively, to increase or limit mevalonate availability. Mevalonate decreased BP in the whole animal without significant change in plasma cholesterol. Incubation of aortas with mevalonate attenuated their reactivity to norepinephrine and increased their response to endothelium-dependent and -independent relaxing factors. Lovastatin, in contrast, had the opposite effect in vivo and in vitro: it increased BP, enhanced vascular response to norepinephrine, and impaired endothelium-dependent and -independent relaxations. Neither agent modified cholesterol vascular content. Alteration of vascular reactivity was also observed in resistance vessels from animals pretreated with lovastatin. Our findings suggest that mevalonate availability is an unrecognized metabolic contributor to vascular tone and BP. They imply that (i) metabolites of the mevalonate pathway other than cholesterol could potentially control vascular functions and cardiovascular hemodynamics, (ii) elevated arterial pressure could be in part the consequence of primary disorders of this pathway, and (iii) pharmacological inhibition of mevalonate production as a means to lower plasma cholesterol may have an adverse impact on other cardiovascular risk factors, such as BP.

Original languageEnglish (US)
Pages (from-to)11728-11732
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume90
Issue number24
StatePublished - Dec 15 1993

Fingerprint

Mevalonic Acid
Blood Vessels
Blood Pressure
Lovastatin
Cholesterol
Hydroxymethylglutaryl CoA Reductases
Norepinephrine
Endothelium-Dependent Relaxing Factors
Hypercholesterolemia
Endothelium
Aorta
Arterial Pressure
Hemodynamics
Maintenance
Pharmacology

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Roullet, J-B., Xue, H., Pappu, A., Roullet, C., Holcomb, S., & Mccarron, D. A. (1993). Mevalonate availability and cardiovascular functions. Proceedings of the National Academy of Sciences of the United States of America, 90(24), 11728-11732.

Mevalonate availability and cardiovascular functions. / Roullet, Jean-Baptiste; Xue, Hong; Pappu, Anuradha; Roullet, Chantal; Holcomb, Scott; Mccarron, David A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, No. 24, 15.12.1993, p. 11728-11732.

Research output: Contribution to journalArticle

Roullet, J-B, Xue, H, Pappu, A, Roullet, C, Holcomb, S & Mccarron, DA 1993, 'Mevalonate availability and cardiovascular functions', Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11728-11732.
Roullet, Jean-Baptiste ; Xue, Hong ; Pappu, Anuradha ; Roullet, Chantal ; Holcomb, Scott ; Mccarron, David A. / Mevalonate availability and cardiovascular functions. In: Proceedings of the National Academy of Sciences of the United States of America. 1993 ; Vol. 90, No. 24. pp. 11728-11732.
@article{65bf16c1ee214dc888347f1294ec0321,
title = "Mevalonate availability and cardiovascular functions",
abstract = "Data delineating the relationship between disorders of cholesterol metabolism and elevated blood pressure (BP) do not exist. We postulated that mevalonate, the metabolic precursor of endogenous cholesterol and the direct product of 3-hydroxy-3-methylglutaryl-CoA reductase, was a contributing factor for the maintenance of vascular tone and systemic BP. We conducted in vivo, ex vivo, and in vitro experiments in normotensive and hypertensive rats, where exogenous mevalonate and lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, were used, respectively, to increase or limit mevalonate availability. Mevalonate decreased BP in the whole animal without significant change in plasma cholesterol. Incubation of aortas with mevalonate attenuated their reactivity to norepinephrine and increased their response to endothelium-dependent and -independent relaxing factors. Lovastatin, in contrast, had the opposite effect in vivo and in vitro: it increased BP, enhanced vascular response to norepinephrine, and impaired endothelium-dependent and -independent relaxations. Neither agent modified cholesterol vascular content. Alteration of vascular reactivity was also observed in resistance vessels from animals pretreated with lovastatin. Our findings suggest that mevalonate availability is an unrecognized metabolic contributor to vascular tone and BP. They imply that (i) metabolites of the mevalonate pathway other than cholesterol could potentially control vascular functions and cardiovascular hemodynamics, (ii) elevated arterial pressure could be in part the consequence of primary disorders of this pathway, and (iii) pharmacological inhibition of mevalonate production as a means to lower plasma cholesterol may have an adverse impact on other cardiovascular risk factors, such as BP.",
author = "Jean-Baptiste Roullet and Hong Xue and Anuradha Pappu and Chantal Roullet and Scott Holcomb and Mccarron, {David A.}",
year = "1993",
month = "12",
day = "15",
language = "English (US)",
volume = "90",
pages = "11728--11732",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "24",

}

TY - JOUR

T1 - Mevalonate availability and cardiovascular functions

AU - Roullet, Jean-Baptiste

AU - Xue, Hong

AU - Pappu, Anuradha

AU - Roullet, Chantal

AU - Holcomb, Scott

AU - Mccarron, David A.

PY - 1993/12/15

Y1 - 1993/12/15

N2 - Data delineating the relationship between disorders of cholesterol metabolism and elevated blood pressure (BP) do not exist. We postulated that mevalonate, the metabolic precursor of endogenous cholesterol and the direct product of 3-hydroxy-3-methylglutaryl-CoA reductase, was a contributing factor for the maintenance of vascular tone and systemic BP. We conducted in vivo, ex vivo, and in vitro experiments in normotensive and hypertensive rats, where exogenous mevalonate and lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, were used, respectively, to increase or limit mevalonate availability. Mevalonate decreased BP in the whole animal without significant change in plasma cholesterol. Incubation of aortas with mevalonate attenuated their reactivity to norepinephrine and increased their response to endothelium-dependent and -independent relaxing factors. Lovastatin, in contrast, had the opposite effect in vivo and in vitro: it increased BP, enhanced vascular response to norepinephrine, and impaired endothelium-dependent and -independent relaxations. Neither agent modified cholesterol vascular content. Alteration of vascular reactivity was also observed in resistance vessels from animals pretreated with lovastatin. Our findings suggest that mevalonate availability is an unrecognized metabolic contributor to vascular tone and BP. They imply that (i) metabolites of the mevalonate pathway other than cholesterol could potentially control vascular functions and cardiovascular hemodynamics, (ii) elevated arterial pressure could be in part the consequence of primary disorders of this pathway, and (iii) pharmacological inhibition of mevalonate production as a means to lower plasma cholesterol may have an adverse impact on other cardiovascular risk factors, such as BP.

AB - Data delineating the relationship between disorders of cholesterol metabolism and elevated blood pressure (BP) do not exist. We postulated that mevalonate, the metabolic precursor of endogenous cholesterol and the direct product of 3-hydroxy-3-methylglutaryl-CoA reductase, was a contributing factor for the maintenance of vascular tone and systemic BP. We conducted in vivo, ex vivo, and in vitro experiments in normotensive and hypertensive rats, where exogenous mevalonate and lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, were used, respectively, to increase or limit mevalonate availability. Mevalonate decreased BP in the whole animal without significant change in plasma cholesterol. Incubation of aortas with mevalonate attenuated their reactivity to norepinephrine and increased their response to endothelium-dependent and -independent relaxing factors. Lovastatin, in contrast, had the opposite effect in vivo and in vitro: it increased BP, enhanced vascular response to norepinephrine, and impaired endothelium-dependent and -independent relaxations. Neither agent modified cholesterol vascular content. Alteration of vascular reactivity was also observed in resistance vessels from animals pretreated with lovastatin. Our findings suggest that mevalonate availability is an unrecognized metabolic contributor to vascular tone and BP. They imply that (i) metabolites of the mevalonate pathway other than cholesterol could potentially control vascular functions and cardiovascular hemodynamics, (ii) elevated arterial pressure could be in part the consequence of primary disorders of this pathway, and (iii) pharmacological inhibition of mevalonate production as a means to lower plasma cholesterol may have an adverse impact on other cardiovascular risk factors, such as BP.

UR - http://www.scopus.com/inward/record.url?scp=0027135815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027135815&partnerID=8YFLogxK

M3 - Article

C2 - 8265617

AN - SCOPUS:0027135815

VL - 90

SP - 11728

EP - 11732

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 24

ER -